A well-known complication of atrial fibrillation for patients to form clots.
EDITOR’S NOTE: Dr. Remer reported this story during a recent edition of Talk Ten Tuesdays.
A while ago, Allen Frady and Dr. Ronald Hirsch were having a lively discussion on LinkedIn regarding atrial fibrillation and the diagnosis of D68.69, Other thrombophilia which is the code used for “secondary hypercoagulable state.” I thought I was going to be able to weigh in quickly and decisively, but I exceeded my character limit, so I am bringing the discussion here.
Primary hypercoagulable states are easier to identify. They are hereditary abnormalities of coagulation where a physiologic anticoagulant pathway is not properly functional. Examples are antithrombin III deficiency, protein C and S deficiencies, and dysfibrinogenemias. The checks and balances of clotting don’t work, so the patient clots excessively.
There are conditions of acquired hypercoagulability which are referred to as secondary hypercoagulable states. Examples of this are pregnancy, hormonal therapy such as birth control pills, malignancy, and hyperlipidemia.
Allen questioned whether we are missing the diagnosis of secondary hypercoagulable state. He referred to a presentation by Dr. Vladimir-Ducarmel Joseph who referenced Virchow’s triad and posed atrial fibrillation as being a hypercoagulable state. Since AF affects approximately 1 percent of the population, Allen wondered whether we are missing a prime opportunity to capture D68.69, a comorbid condition or complication (CC).
Virchow’s triad is a pathophysiological concept to explain an increased likelihood of developing thrombi. The three components of the triad are stasis or abnormal blood flow, endothelial injury, and hypercoagulability caused by abnormal blood constituents. The more factors the patient has, the higher the risk of developing a clot.
The title of D68.69 is Other thrombophilia. Thrombophilia is defined in the Merriam-Webster medical dictionary as, “a hereditary or acquired disorder marked by an abnormal increase in the tendency of blood to clot and higher than normal risk of thrombosis.”
It is a well-known complication of atrial fibrillation for patients to form clots, usually in the atrial appendage, and for these clots to be propelled into the brain circulation causing stroke. The risk is about 5 percent, per year on average. The older the patient, the higher the risk. Patients are often placed on anticoagulation prophylactically. They have a higher than normal risk of thrombosis, but thrombi are not forming on the basis of an abnormal tendency for the blood to clot.
My opinion is just having a propensity for developing a clot, especially in a specific location, does not constitute a hypercoagulable state. Thrombogenic, yes, hypercoagulable, no. Having an injury or a previous DVT does predispose a patient to developing a clot. That is not a hypercoagulable state to me. I think the key question is, “Is the patient generally predisposed to a clot anywhere in their body because their coagulation system is not functioning properly?”
The higher than normal risk of thrombosis from other thrombophilia is due to an abnormal tendency of the blood to clot, not situational. Patients with atrial fibrillation don’t have blood with a higher tendency to clot; the provider does a risk-benefit analysis and renders their blood less likely to clot with extrinsic anticoagulation.
Should the provider be documenting all pregnant women, all patients on hormones, all patients with malignancies with D68.69? Not unless they are taking those secondary hypercoagulable states into account and assessing or treating it. The condition must meet the criteria of a secondary diagnosis.
As I think about everything nowadays, what about COVID-19? Experts are not sure of the mechanism, but the coronavirus does seem to make some patients hypercoagulable. They have a tendency to develop clots in various locations. This does legitimately meet secondary hypercoagulable status.
The key is how did the provider document it? Are they treating it with anticoagulation? I think this is query-worthy, because epidemiologically speaking, knowing the incidence of hypercoagulability in COVID-19 would be important.
My vote is atrial fibrillation is not a “secondary hypercoagulable state.” There is literature that refers to it this way but prepare yourself for a denial appeal unless there are extenuating circumstances.
This week Blue Cross Blue Shield published an article titled “Study suggests AI is boosting hospital billing.” The study was based on data analyzed by
The Centers for Medicare & Medicaid Services (CMS) operates a surveillance platform called the Fraud Prevention System (FPS) that analyzes Medicare claims across the full
Please log in to your account to comment on this article.
Sepsis sequencing continues to challenge even experienced coding and CDI professionals, with evolving guidelines, documentation gaps, and payer scrutiny driving denials and data inconsistencies. In this webcast, Payal Sinha, MBA, RHIA, CCDS, CDIP, CCS, CCS-P, CCDS-O, CRC, CRCR, provides clear guideline-based strategies to accurately code sepsis, severe sepsis, and septic shock, assign POA indicators, clarify the relationship between infection and organ dysfunction, and align documentation across teams. Attendees will gain practical tools to strengthen audit defensibility, improve first-pass accuracy, support appeal success, reduce denials, and ensure accurate quality reporting, empowering organizations to achieve consistent, compliant sepsis coding outcomes.
Expert presenters Kathy Pride, RHIT, CPC, CCS-P, CPMA, and Brandi Russell, RHIA, CCS, COC, CPMA, break down complex fracture care coding rules, walk through correct modifier application (-25, -57, 54, 55), and clarify sequencing for initial and subsequent encounters. Attendees will gain the practical knowledge needed to submit clean claims, ensure compliance, and stay one step ahead of payer audits in 2026.
Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.
Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
